Cargando…
Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
BACKGROUND: Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, but rare o...
Autores principales: | Zhou, Jinhan, Mao, Qinghua, Li, Yining, Li, Zhiyong, He, Hong, Chen, Qianming, Liu, Chuanxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561900/ https://www.ncbi.nlm.nih.gov/pubmed/34727912 http://dx.doi.org/10.1186/s12903-021-01901-9 |
Ejemplares similares
-
Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210
por: Chen, Xuelian, et al.
Publicado: (2019) -
Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement
por: Finlay, William J.J., et al.
Publicado: (2018) -
Oral Propranolol for Treatment of Pediatric Capillary Hemangiomas
por: Aletaha, Maryam, et al.
Publicado: (2012) -
Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report
por: Zhu, Hong, et al.
Publicado: (2019) -
Juvenile capillary hemangioma
por: Gajendra, Smeeta, et al.
Publicado: (2016)